# Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

> **NCT02100930** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 69 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** Anti-GD2 3F8 Monoclonal Antibody
- **DRUG:** GM-CSF (granulocyte-macrophage colony-stimulating factor)
- **DRUG:** oral isotretinoin

## Key facts

- **NCT ID:** NCT02100930
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2019-03-07
- **Final completion:** 2019-03-07
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2020-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02100930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02100930, "Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02100930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*